<DOC>
	<DOC>NCT01866150</DOC>
	<brief_summary>This cross-sectional, non-interventional, retrospective chart review will compare the efficacy and safety of biologic monotherapy and biologic and methotrexate combination therapy in patients with rheumatoid arthritis who have had an inadequate response to prior treatment with disease-modifying anti-rheumatic drugs including methotrexate. Data will be collected from patients who have been on first-line biologic treatment for at least 6 months.</brief_summary>
	<brief_title>A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Diagnosis of rheumatoid arthritis by a rheumatologist Patients who have responded inadequately to methotrexate or diseasemodifying antirheumatic drugs (DMARDs) and are being prescribed a biologic in monotherapy or in combination with methotrexate and other classical DMARDs as per NICE guidelines Primary diagnosis of a condition other than rheumatoid arthritis Current treatment with a biologic in combination without methotrexate Prior treatment with an experimental agent for rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>